CLOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CLOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Clover Health Investments's Revenue for the three months ended in Sep. 2024 was $331 Mil. Clover Health Investments's average Accounts Receivable for the three months ended in Sep. 2024 was $0 Mil.
The historical data trend for Clover Health Investments's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clover Health Investments Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Receivables Turnover | - | - | - | - | - |
Clover Health Investments Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Receivables Turnover | Get a 7-Day Free Trial | - | - | - | - | - |
For the Healthcare Plans subindustry, Clover Health Investments's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Plans industry and Healthcare sector, Clover Health Investments's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Clover Health Investments's Receivables Turnover falls into.
Receivables Turnover measures the number of times a company collects its average accounts receivable balance.
Clover Health Investments's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as
Receivables Turnover (A: Dec. 2023 ) | |||||||
= | Revenue | / | Average Total Inventories | ||||
= | Revenue (A: Dec. 2023 ) | / ( | (Accounts Receivable (A: Dec. 2022 ) | + | Accounts Receivable (A: Dec. 2023 )) | / | count ) |
= | 2033.72 | / ( | (0 | + | 0) | / | 1 ) |
= | 2033.72 | / | 0 | ||||
= | N/A |
Clover Health Investments's Receivables Turnover for the quarter that ended in Sep. 2024 is calculated as
Receivables Turnover (Q: Sep. 2024 ) | |||||||
= | Revenue | / | Average Total Inventories | ||||
= | Revenue (Q: Sep. 2024 ) | / ( | (Accounts Receivable (Q: Jun. 2024 ) | + | Accounts Receivable (Q: Sep. 2024 )) | / | count ) |
= | 330.986 | / ( | (0 | + | 0) | / | 1 ) |
= | 330.986 | / | 0 | ||||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clover Health Investments (NAS:CLOV) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Thank you for viewing the detailed overview of Clover Health Investments's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Vivek Garipalli | director, 10 percent owner, officer: Executive Chairperson | C/O CLOVER HEALTH INVESTMENTS, CORP., 725 COOL SPRINGS BLVD., SUITE 320, FRANKLIN TN 37067 |
Anna U Loengard | director | C/O CLOVER HEALTH INVESTMENTS, CORP., 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067 |
Karen Soares | officer: General Counsel & Secretary | 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067 |
Clover Health Investments, Corp. /de | officer: Chief Technology Officer | 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067 |
Andrew Toy | director, officer: Chief Executive Officer | C/O CLOVER HEALTH INVESTMENTS, CORP., 725 COOL SPRINGS BLVD., SUITE 320, FRANKLIN TN 37067 |
Scott J. Leffler | officer: Chief Financial Officer | C/O CLOVER HEALTH INVESTMENTS, CORP., 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067 |
Brady Patrick Priest | officer: CEO of Home Care | C/O CLOVER HEALTH INVESTMENTS, CORP., FRANKLIN TN 37067 |
Demetrios L. Kouzoukas | director | C/O CLOVER HEALTH INVESTMENTS, CORP., 725 COOL SPRINGS BLVD., SUITE 320, FRANKLIN FL 37067 |
Aric R Sharp | officer: CEO of Value-Based Care | C/O CLOVER HEALTH INVESTMENTS, CORP., 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067 |
Wai Conrad | officer: Chief Technology Officer | 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067 |
Joseph Richards Martin | officer: General Counsel | C/O LOUISIANA-PACIFIC CORPORATION, 414 UNION STREET, SUITE 2000, NASHVILLE TN 37219 |
Carladenise Armbrister Edwards | director | C/O CLOVER HEALTH INVESTMENTS, CORP., 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067 |
Chelsea Clinton | director | C/O IAC 555 W 18TH STREET, NEW YORK NY 10011 |
Jamie L. Reynoso | officer: CEO of Medicare Advantage | C/O CLOVER HEALTH INVESTMENTS, CORP., 725 COOL SPRINGS BLVD., SUITE 320, FRANKLIN TN 37067 |
Chamath Palihapitiya | 10 percent owner, other: See Remarks | THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025 |
From GuruFocus
By Marketwired • 04-23-2024
By Marketwired • 10-29-2024
By Marketwired • 04-22-2024
By GuruFocus News • 11-05-2024
By Marketwired • 08-22-2024
By GuruFocus News • 11-07-2024
By Marketwired • 05-01-2024
By Marketwired • 09-03-2024
By Marketwired • 11-06-2024
By GuruFocus Research • 06-21-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.